← BackIDEXX LABORATORIES INC /DE · In Vitro & In Vivo Diagnostic SubstancesIDXX
Low riskNext report: In 5 days (est.)
The short versionA high-quality, profitable business with steady sales.
Going well
- Profitable every year for 10 years
- Sales up 10% last year
- Brings in more cash than it spends
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 4.1% to their holdings in the quarter ending June 2026 (576 bought, 604 sold)
- Held by Ray Dalio (Bridgewater), Terry Smith (Fundsmith)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$570.28+1.8% that day
- Company value
- $44.9B
- Share price times all shares
- Price vs profit (P/E)
- 40.1x
- You pay about $40 for each $1 of yearly profit
- Price vs sales
- 9.9x
- Company value is 9.9 times a year of sales
- Cash vs value
- 0%
- Cash as a share of company value
- Debt vs value
- 1%
- Debt as a share of company value
From IDXX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$1.2B+9.7% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $4.6B, up 13% from the 12 months before. Over 5 years, sales grew about 9.7% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.66.2%
- PassDebt under half of equityNot relying on borrowed money.0.28x equity
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.24.6%
- PassProfitable every yearSteady profits, not one good year.10 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$1.1B
- PassShare count not growingNot diluting owners. Falling means buybacks.-4.2% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.61.8%
- Revenue
- $4.3B
- +10.4% vs prior year
- 5-year growth
- +9.7%/yr
- revenue, per year
- Total debt
- $450.0M
- 0.28x equity
- Current ratio
- 1.23x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $1.2B
- +9.7% YoY
- EPS
- $4.27
- vs $3.63
- Op. margin
- 35.0%
- +1.4 pts
- Gross margin
- 64.0%
- +1.4 pts
- Free cash flow
- $322.5M
- Share count
- -2.1%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 0.5
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+4.1%Institutions added 4.1% to their holdings. 576 bought, 604 sold.
Shares held by institutions74.5M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-1.7%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.3x · $449.9M debtShares outstandingLatest reported
79MNext reportIn 5 days (est.)Estimated from the same quarter last year
- Results filedAug 4
- Results filedMay 5
- Results filedFeb 2
- Results filedNov 3, 2025
- Results filedAug 4, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.